4:02 PM
 | 
Apr 10, 2019
 |  BC Extra  |  Company News

Gilead cuts cardiopulmonary sales reps

Gilead said it will lay off about 150 cardiopulmonary sales representatives due to the anticipated market entry of generic versions of Letairis ambrisentan and Ranexa ranolazine. The decision was put into motion almost two years ago, a Gilead Sciences Inc. (NASDAQ:GILD) spokesperson told BioCentury (see "O'Day's Expansive Task at Gilead").

Letairis, a selective endothelin A receptor antagonist, is marketed to treat pulmonary arterial hypertension (PAH). Ranexa, a selective late sodium current blocker, is marketed to treat chronic angina.

Gilead reported 2018 U.S. sales for Letairis and Ranexa of $943 million and $758 million, respectively, which together represented about 8% of the company’s overall sales. Ranexa’s patents expire next month, while multiple generics are already approved for Letairis.

Gilead, which has 11,000 employees, declined to disclose the size of its sales force.

Gilead gained $1.31 to $67.40 on Wednesday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD